| Document |
Document Title |
|
WO/2024/110994A1 |
The present disclosure relates to process for the preparation of Ledipasvir (I) or of its pharmaceutically acceptable salts. The present disclosure also provides novel intermediates (IV–XI) that are used in the synthesis of Ledipasvir....
|
|
WO/2024/109817A1 |
Purification process for conjugate (S) -3- ( ( ( (S) -1- ( (S) -2- (6-methoxynaphthalen-2-yl) propanoyloxy) ethoxy) carbonyl-amino) methyl) -5-methylhexanoic acid is described herein.
|
|
WO/2024/109665A1 |
The present invention belongs to the field of biomedicines. Disclosed are carbamate-bond-containing lipid compounds and the use thereof. The lipid compounds are compounds of the following structure, the definition of each group being as ...
|
|
WO/2024/108311A1 |
A method of assessing a risk of developing Alzheimer's disease (AD) and of diagnosing AD in a subject comprising: comparing a level of extracellular vesicles (EVs) that are positive for at least one biomarker in a biofluid sample taken f...
|
|
WO/2024/102404A1 |
The subject matter described herein is directed to methods of preparing compounds of general Formula I: or a salt or solvate thereof.
|
|
WO/2024/094526A1 |
The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer.
|
|
WO/2024/094125A1 |
Provided herein are lipid compounds, e.g., a compound of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, e.g., a compound of Formula (I).
|
|
WO/2024/094961A1 |
The present invention relates to a method of producing a moisture-cure resin composition, the method comprising the steps of: preparing a hydroxy alkyl urethane modifier having the formula:(I); where: R1 is an amine residue; and R2 and R...
|
|
WO/2024/092892A1 |
Provided are an edoxaban intermediate and a preparation method therefor. Specifically, the edoxaban intermediate includes intermediate compounds of formula I and formula II. The preparation method comprises: subjecting a compound of form...
|
|
WO/2024/089159A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, pharmaceutical compositions comprising the compounds and methods for synthesising compounds according to formula I. This invention further...
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/089666A1 |
An efficient, economical and continuous process for the preparation of L-lysine-D- amphetamine dimesylate.
|
|
WO/2024/085208A1 |
This compound is a compound represented by formula (1). [In the formula, n represents an integer from 1-3. L1 represents a possibly branched, (n + 1)-valent linking group (but excluding chain saturated aliphatic hydrocarbon groups). ...
|
|
WO/2024/075760A1 |
The present invention addresses the problem of providing: a novel method for producing a N-acetyl-D-galactosamine ligand-oligonucleotide conjugate, particularly a novel method for producing a N-acetyl-D-galactosamine unit; and a novel in...
|
|
WO/2024/075535A1 |
In the present invention, there is employed a resist composition having, as a base resin, a polymer compound that has constituent units derived from a compound expressed by general formula (a0−m). In the formula, W is a polymerizable-g...
|
|
WO/2024/071178A1 |
Provided is an industrially useful method for producing an alkylsilyloxy-substituted benzylamine compound, in which impurities are easily removed and the method does not involve an alkylsilyloxy-substituted benzyl compound that is an int...
|
|
WO/2024/056678A1 |
The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptak...
|
|
WO/2024/053494A1 |
This (meth)acrylic group-containing polycarboxylic acid compound is represented by general formula (1) and/or general formula (2). R1 and R3 denote alkylene groups. R2 denotes a single bond or an alkylene group. R4 denotes an alkylene gr...
|
|
WO/2024/053350A1 |
The purpose of the present invention is to provide a method for producing an aminoazide compound and a diamine compound in which the formation of undesired diastereomers is inhibited and which has good diastereoselectivity. Provided is a...
|
|
WO/2024/054321A1 |
Non-triazole compounds are provided that can be effective to inhibit corrosion of a corrodible metal surface in an aqueous system. The non-triazole compounds show comparable or better corrosion inhibition as compared to conventional tria...
|
|
WO/2024/046279A1 |
The present invention relates to a compound of formula (I), which has a plurality of crystal forms. The crystal forms of the compound show good stability in addition to higher purity, especially crystal form I, crystal form II and crysta...
|
|
WO/2024/044728A1 |
The present disclosure relates to PEGylated lipid compounds and pharmaceutically acceptable salts thereof. Such compounds are useful, for example, as constituent parts of lipid nanoparticle (LNP) formulations for delivery of various acti...
|
|
WO/2024/024965A1 |
The present invention addresses the problem of providing a method for producing an O-substituted serine derivative, which makes it possible to produce an O-substituted serine derivative in fewer steps. The present inventors have made ext...
|
|
WO/2024/019936A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2024/011415A1 |
Disclosed in the present invention is a method for preparing an o-iodophenyl compound, wherein an iodobenzene compound and an amide compound as raw materials are reacted in the presence of sodium hydride or n-butyllithium and a solvent t...
|
|
WO/2024/012565A1 |
The present invention provides a memantine derivative or a stereoisomer, solvate or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a use in preparing a drug for preventing and/or treating central nerv...
|
|
WO/2024/012397A1 |
The present invention relates to a compound having a structure represented by formula I, formula II, formula III, formula IV, formula V or formula VI, or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical compos...
|
|
WO/2024/007851A1 |
A catalyst for amide synthesis and preparation and use thereof are disclosed. The catalyst is a thio or seleno pyranodipyrimidine compound and has a simple and novel structure, high catalytic efficiency, and good atom economy. The cataly...
|
|
WO/2023/233164A1 |
Compounds of formula (I) wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrom...
|
|
WO/2023/227757A1 |
The invention provides protected ortho-quinone compounds comprising a group represented by: Formula (I) where -Ar- is optionally substituted phenylene, -X is selected from -NH2, -OH and -SH, and the protected forms of each, -W- is option...
|
|
WO/2023/222870A1 |
The present invention generally relates to the field of ionizable (also termed cationic) lipids,and in particular provides a novel type of such lipids as represented by any of the formulae disclosed herein. The present invention further ...
|
|
WO/2023/219152A1 |
One aspect of the present invention relates to a method for producing a salt of an amino acid, a salt of a peptide compound, or a solvate of either one of the salts, the method comprising the following steps (A) and (B). Step (A): a st...
|
|
WO/2023/208020A1 |
Disclosed are an intermediate of a polyamine derivative pharmaceutical salt, a preparation method therefor, and use thereof. The intermediate compound has the following structure: (I), which can be used to prepare a polyamine derivative ...
|
|
WO/2023/206874A1 |
A sacubitril intermediate, a preparation method therefor, and use thereof. A key intermediate N-Boc amino alcohol represented by formula (10) or formula (10-a) can be efficiently prepared. The intermediate can be used to prepare a neutra...
|
|
WO/2023/203254A2 |
The present invention relates to compounds inhibiting the toxic activity of extrasynaptic NMDA receptors, in particular by inhibiting the formation of NMDA receptor/TRPM4 complexes. In particular, the present invention relates to diamine...
|
|
WO/2023/205237A1 |
Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are...
|
|
WO/2023/200913A1 |
Described herein are methods of synthesizing 5-chloro-2-((ethoxycarbonyl)amino)-3- methylbenzoic acid and derivatives thereof.
|
|
WO/2023/196444A1 |
Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component o...
|
|
WO/2023/192145A1 |
Methods of synthesizing (R)-N-(4-(4-(3-chloro-5-ethyl-2- methoxyphenyl) piperazin-l-yl)-3-hydroxybutyl)-l H-indole-2- carboxamide (compound 8) are described as well as intermediate compounds of formulae 5-7, 9 and 14 used in said methods.
|
|
WO/2023/179462A1 |
Disclosed in the present invention are a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which solve the problem of there being an urgent need to develop cationic lipids with high ...
|
|
WO/2023/174062A1 |
Disclosed is a method for preparing nilutamide and an intermediate thereof. The method comprises the following steps: at a temperature of 25 °C to 160 °C, using 4-nitro-3-trifluoromethylaniline represented by formula (I) and a compound...
|
|
WO/2023/177877A1 |
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist co...
|
|
WO/2023/168889A1 |
Disclosed herein are a preparation method for an alicyclic carbamate and the use thereof. The preparation method comprises the following steps: mixing a carbamate containing an aromatic ring, a catalyst and a solvent, and then introducin...
|
|
WO/2023/167333A1 |
[Problem] To provide a method for fluorescence imaging of cancer cells or tissues that express LAT1. [Solution] This method for visualizing cancer cells or tissues comprises: (a) a step for introducing a compound represented by general f...
|
|
WO/2023/164889A1 |
Disclosed are a method for preparing codeine and a derivative and intermediate thereof. Simple, cheap and easily-available commercially available compounds are used as starting materials in the present invention, various intermediates th...
|
|
WO/2023/161505A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity, pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditi...
|
|
WO/2023/161597A1 |
A two-part epoxy resin composition is provided comprising: a first resin part comprising a modified hydroxy alkyl urethane and an epoxy component; and a second resin part comprising an amine component; wherein the modified hydroxy alkyl ...
|
|
WO/2023/160702A1 |
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a ...
|
|
WO/2023/158634A1 |
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatm...
|
|
WO/2023/144798A1 |
Certain embodiments of the invention provide ionizable lipids having optimized clearance properties. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid ...
|
